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Summary Two hydroxyl containing dithiocarbamates, sodium N-methyl-D-glucamine dithiocarbamate (NaG)
and sodium dihydroxyethyl dithiocarbamate (NaY) have been examined as agents for the control of the renal
dysfunction in rats given cisplatin. Of these, NaG was found to be the more effective in controlling such renal
dysfuncfion when administered at 1 and 3 h after 5 mg cisplatin kg-', i.p. Renal function was examined 5 days
after the administration of cisplatin by measurement of serum and urinary levels of creatinine and urea,
creatinine clearance, serum and urinary levels of Na+, K+, Mg2", Ca2", as well as the concentrations of these
ions in the renal medulla and cortex. Treatment of rats given cisplatin with NaG at 1 and 3 h post cisplatin
resulted in indices of renal function which were not significantly different from those of animals which had
received no cisplatin. The sole difference was found to be a slight increase in renal cortical Na+ concentration.
Impairment in renal function is a significant adverse effect of
cisplatin (cis-diamminedichloroplatinum(II)), a widely used
antineoplastic agent (Safirstein et al., 1987; Natochin et al.,
1987). The use of sodium diethyldithiocarbamate has been
found to lead to the reduction of several aspects of this
cisplatin-induced renal damage (Borch & Pleasants, 1979). In
experiments in rats (Borch et al., 1980; Jones et al., 1986) and
in clinical trials (Qazi et al., 1988) dithiocarbamates nor-
malized several measures of cisplatin renal toxicity without
any loss of the antineoplastic activity of cisplatin. In a
previous study it was shown that the changes in both serum
urea and serum creatinine values after cisplatin administra-
tion in rats may be reduced by pretreatment with organic
acids and bases (Natochin et al., 1987), though there was no
reduction of renal platinum accumulation or renal tissue
swelling when these were used. The lack of information on
the effect of dithiocarbamates on certain aspects of cisplatin
nephrotoxicity lead us to investigate the effect of dithiocar-
bamate treatment on several of these: the ability of the
kidney to excrete water and electrolyte's, the water and
electrolyte content in renal tissue, and platinum accumulation
in the kidney. In the present study we examine the effect of
dithiocarbamates on cisplatin-induced renal toxicity as
measured by these parameters. The dithiocarbamates used
were previously reported as inhibitors of cisplatin nephrotox-
icity (Jones et al., 1986). These are the hydroxyl-containing
dithiocarbamates sodium dihydroxyethyl dithiocarbamate
(NaY) and sodium N-methyl-D-glucamine dithiocarbamate
(NaG).
Materials and methods
All experiments were carried out using female Wistar rats
weighing between 140-160 g. The animals were injected
intraperitoneally with cisplatin (Bristol Laboratories, Syra-
cuse, New York) at a dose of 5 mg kg-' body weight. A
preliminary study showed that intravenous or intraperitoneal
administration of the cisplatin followed by dithiocarbamate
administration resulted in equivalent protection against neph-
rotoxicity and equal decreases in renal platinum levels. For
those animals also given a dithiocarbamate, the dithiocar-
bamate was administered at a level of 1.71 mmol/kg'I i.p. at
I and 3 h post cisplatin, i.e., 350 mg NaY kg-' or 500 mg
NaG kg-' at each time. NaY and NaG were prepared as
described previously (Shinobu et al., 1983; Shinobu et al.,
1984). On the fifth day following cisplatin administration a
water load of 5 ml per 100 g of body weight was instilled into
the stomach via a gastric tube and urine was then collected
for the next 2h. Animals were subsequently decapitated
under light ether anesthesia and the kidneys were immedi-
ately removed. The water content of the renal tissue was
determined by drying at 105°C and electrolyte composition of
dry solids was measured after ashing in concentrated nitric
acid. The concentration of sodium and potassium in serum,
urine and tissue samples was measured with a Flapho-4 flame
photometer (Zeiss) and calcium and magnesium were
determined by means of a Hitachi 508 atomic absorption
spectrophotometer. The urea concentration was measured by
reaction with diacetyl monoxime, the creatinine by reaction
with picric acid, and the platinum content by neutron activa-
tion analysis (Zedgenidze et al., 1980). Statistical evaluations
of data were made by means of the Student's t-test.
Results
The glomerular filtration rate (GFR), estimated from creatin-
ine clearance (Ccr) values in Table I, markedly decreased on
the fifth day following cisplatin administration, dropping to
40% of the control value (Table I). The administration of
NaG fully prevented the reduction of the GFR, while NaY
was less effective in this respect.
In animals treated with cisplatin and NaG and subse-
quently given a water load, the water excretion (V) was
practically equal to that in control rats (Table I). However,
the combination of cisplatin with NaY did not prevent a
reduction of water load excretion nor a decrease of the
creatinine clearance following cisplatin administration (Table
I). Cisplatin treatment in the rat resulted in a decrease in
GFR and a rise in both serum creatinine and urea levels;
these were obviated by NaG treatment, (Table I).
The regulation of ionic balance by the kidney after cis-
platin treatment was relatively effective in maintaining ionic
homeostasis on the whole, though there were a moderate
increase in the serum magnesium level and a decrease in the
serum calcium level. Treatment with NaG eliminated these
disturbances in serum composition (Table II). There were a
few significant differences among the groups in the excretion
of electrolytes by the kidney during the 2 h following the
administration of the water load (Table II); the excretion of
calcium is modestly elevated in the animals receiving cis-
platin.
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Table I Diuresis (V), serum creatinine (Pc,), serum urea(Pur), urinary creatinine (Ucr) and urinary urea (Uu,) in rats on the
fifth day after cisplatin (5 mg kg-' i.p.) administration
V Ccr
mlhr-' mlh-'
100g' body PC, Ucr 100g-' body Pur Uur
Group n weight mgdl- mg dl-' Ucr/Pc. weight mgdl- mgdl-I
Control 10 1.62+ 1.19 0.78±0.19 15.5± 1.3 20.6±6.6 33.3±9.5 37.1±4.4 628± 193
Cisplatin 8 1.38±0.45 1.95±0.79a 15.8±4.2 9.2±12.8a 13.6±7.9a 146±96.5a 651 ±286
Cisplatin + NaY 8 1.15±0.68 1.32±0.82 19.2±7.6 15.5±4.5 17.5± 17.ob 80.0±82.1 807±456
Cisplatin + NaG 8 1.67±0.40 0.79±0.25 14.2± 1.1 19.1± 5.1 32.0± 12.2 43.6± 10.5 515± 113
Results are expressed as mean values±s.d. 'Significantly different from control values, P,.0.01. bSignificantly different
from control values, P<0.05.
Table II Concentrations in serum (P, mmol 1 ) and excretion ofelectrolytes bythe kidney (U-V,ymol h-' 100g' bodyweight)following a water
load on the fifth day after cisplatin administration (5 mgkg-', i.p.)
UN. V UK- V UCa" V uMg. V
PN. p -molh P pmolh- PC. pimolh- PMg j.molh-I
Group n mmol/1-' 100g-I wt mmolV' 100g-I wt mmol ' 100g-I wt mmoltI' 100g-I wt
Control 10 139±8.9 41.0±41.4 4.7±0.79 12.7±8.66 3.10±0.51 0.20±0.09 0.78±0.16 1.62±0.88
Cisplatin 8 137±4.2 21.4±15.7 4.2±0.65 11.7±2.21 2.49±0.45a 0.49±0.31a 1.04±O.14b 1.18±0.57
Cisplatin + NaY 8 137±5.9 25.0±25.4 4.2±0.96 8.38±6.17 3.06± 1.10 0.45±0.23b 0.92±0.23 1.52±0.76
Cisplatin + NaG 8 138±2.3 24.4±15.7 4.5±1.21 10.7±4.13 2.85± 1.02 0.46±0.51 0.86±0.28 1.18±0.31
Results are expressed as mean values±s.d. aSignificantly different from control values, P<0.05. bSignificantly different from control values,
P<0.01.
For those animals given cisplatin only, the kidney weight
increased by 65% (Table III) by the fifth day following
cisplatin administration. The causes of this increase in kidney
weight included both swelling and an increase in dry solids.
This latter may be due to increased blood content in renal
tissue. The use of NaG prevented these changes; the use of
NaY did not (Table III).
The swelling of the kidneys was accompanied by an in-
crease in the sodium and calcium contents of renal cortex
(Table III). These changes of electrolyte composition of the
cortex were largely prevented by the administration of NaG.
The protective action of NaY was very slight.
The administration of cisplatin resulted in less pronounced
alterations in the electrolyte composition of the outer med-
ulla (Table III). The sodium content was not increased. The
potassium and magnesium contents in the outer medulla
were the same in the NaG treated animals as in the control.
NaY treatment did not result in the maintenance of magnes-
ium levels in the outer medulla.
The platinum content of the renal tissue in the unprotected
animals was found to be almost three-fold greater than that
in animals treated with dithiocarbamates (Table IV). For the
cisplatin-only treated animals the renal platinum content was
found to be 29.1 ± 1.1 ppm/dry weight on the fifth day fol-
lowing platinum administration. The administration of either
NaG and NaY resulted in lower platinum levels with a
reduction to about 40% of the levels in animals given only
cisplatin. No significant difference was found between the
renal platinum levels obtained with these two compounds,
though the extent of the protection furnished by these two
compounds was significantly different with respect to the
creatinine clearance (Table I) and kidney weights (Table III).
Discussion
The results obtained indicate that NaG is superior to NaY in
preventing the nephrotoxic effects found 5 days after cisplatin
is given to rats i.p. at a dose of 5 mg cisplatin kg-' body
weight. The postulated mechanism of dithiocarbamate action
is via competitive chelation and removal of platinum coord-
inated to protein-bound -SH groups of the kidney tubule
cells (Borch & Pleasants, 1979; Borch et al., 1980). The
Table III Kidney weights and water and electrolyte contents in renal tissue on the fifth day after cisplatin
administration (5 mg kg-', i.p.)
Kidney wt (mg 100g-' body wt)
Group n Wet Dry
Control 10 800±98 182.5±20.5
Cisplatin 8 1320±306b 244.5±26.0b
Cisplatin + NaY 8 1125± 125b 228.1 ±21.5b
Cisplatin + NaG 8 860±96 186.7± 18.1
Cortex values (ions in pmolg' wet weight):
H20
Group n Na K Ca Mg (g/g dry wt)
Control 10 55.8±5.47 81.9±6.35 1.66±0.41 7.66±0.47 2.95±0.25
Cisplatin 8 64.8±7.47a 72.8±7.44b 3.49± 1.50b 7.47±0.62 4.10±0.79b
Cisplatin + NaY 8 67.5±6.28b 78.4± 3.42 2.54± 1.33 7.11±0.59 3.42±0.28b
Cisplatin + NaG 8 61.5±4.67a 79.9±5.09 1.80±0.20 7.80±0.37 3.03±0.34
Outer medulla (ion values inp.mol/g-' wet weight)
H20
Group n Na K Ca Mg (g/g dry wt)
Control 10 61.9±6.57 79.4±3.03 2.28± 1.23 7.60±0.25 4.16±0.73
Cisplatin 8 58.2± 10.3 76.6±8.10 4.09±2.66 6.58±0.68b 5.50±0.76a
Cisplatin + NaY 8 56.3 ± 5.69 80.3±4.02 2.88± 2.04 7.04± 0.54a 4.33±0.96
Cisplatin + NaG 9 58.7±4.75 77.4± 5.49 1.75± 0.37 7.65±0.40 4.31±0.28
Results are expressed as means±s.d.; aSignificantly different from control, P<0.05; bSignificantly
different from control, P<0.01.
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Table IV Platinum content in renal tissue on the fifth day after
cisplatin administrationa
Platinum content
Group (fLgg-', dry weight)
Control 0
Cisplatin 29.1 ±3.5
Cisplatin + NaY 11.3±4.0b
Cisplatin + NaG 10.9± 1.7b
aEachanimalinthecisplatingroups wasgiven 5 mgcisplatin kg-' i.p.
Those animals in the treated groups received either NaY (350 mg kg-')
or NaG (500 mg kg-') at I and 3 h post cisplatin. Five days later the
animals were dissected and tissues removed foranalysis. The results are
expressed as mean±s.d. bSignificantly different from cisplatin,
P<0.01.
distribution of platinum in the kidney following cisplatin
administration indicates its specific localisation in the S3
segment of the proximal nephron (Safirstein et al., 1987) and
the removal of the platinum from its principal site in produc-
ing cellular toxicity should alleviate the renal toxicity, pro-
vided this is done soon enough after the administration of
the cisplatin. The results obtained show that the administra-
tion ofdithiocarbamates was followed by a substantial reduc-
tion of renal platinum levels (Table IV). However, the results
also demonstrate equal renal platinum levels for rats treated
with NaY and NaG, though the degree of renal protection
achieved by administration of NaG was much greater. Simi-
lar effects were observed in earlier studies on cisplatin
nephrotoxicity in rats with preliminary administration of
organic acids and bases: the renal protection provided by
these latter materials was not accompanied by a reduced
platinum accumulation in renal tissue (Natochin et al., 1987).
The lack of a correlation between renal platinum levels and
the degree of renal damage in animals treated to reduce the
nephrotoxic action of the cisplatin has been found for choline
chloride, para-aminohippurate and ethacrynic acid (Natochin
et al., 1989) as well as L-methionine (Basinger et al., 1990). A
similar lack of correlation in other tissues has been found in
experiments in which circadian rhythms were utilised to select
optimum times for the administration of carboplatin (Bough-
attas et al., 1988).
A large portion of the total platinum that accumulates in
kidney cells following cisplatin administration is a product of
the biotransformation of cisplatin and these products are not
mutagenic (Safirstein et al., 1984). As the mutagenic activity
of platinum coordination complexes is correlated with their
cellular toxicity (Lecointe et al., 1979), the loss of muta-
genicity suggests that such products are less toxic.
It is possible that the differences in the reduction of
nephrotoxicity for the two compounds examined here, in
spite of the equal reductions of renal platinum levels,
involves some specific interaction of the dithiocarbamates
with cellular macromolecules which results in a reduced cis-
platin binding or in an enhanced level of a non-toxic plat-
inum compound. The results obtained here are of interest in
showing that renal electrolyte homeostasis may not be per-
fectly preserved subsequent to cisplatin administration even
in cases where compounds such as dithiocarbamates are
administered to protect renal function. While these com-
pounds are capable of reducing renal platinum levels and of
maintaining serum levels of creatinine and urea, one may not
assume from such data that renal control of electrolyte
homeostasis is unimpaired. Most previous studies of the use
of various compounds for the protection of renal function
against the action of cisplatin have concentrated on the
serum non-electrolytes, creatinine and urea, and paid scant
attention to electrolyte homeostasis. The present results sug-
gest that this oversight might be unjustified, particularly as
the dosage of cisplatin is increased.
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